Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 37 for:    AMINOCAPROIC ACID

Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02655653
Recruitment Status : Completed
First Posted : January 14, 2016
Last Update Posted : May 5, 2016
Sponsor:
Information provided by (Responsible Party):
Montefiore Medical Center

Brief Summary:
The investigators primary objective is to compare the effectiveness of epsilon-aminocaproic acid (EACA) and tranexamic acid (TA) in reducing bleeding and transfusion in cardiac surgery, with the hypothesis that TA is more effective. The investigators also seek to further examine the clinical benefits and adverse effects profiles of epsilon-aminocaproic acid and tranexamic acid.

Condition or disease Intervention/treatment Phase
Bleeding Drug: Epsilon-aminocaproic acid administered Drug: Tranexamic Acid administered Not Applicable

Detailed Description:

This is a single center double blinded randomized controlled study comparing the effectiveness of epsilon-aminocaproic acid (EACA) and tranexamic acid (TA) in reducing 24hour blood transfusion and chest tube drainage. From October 2008 to September 2011, patients greater than 18 years of age, scheduled for cardiac surgery requiring CPB were consented. Eligible operations included; coronary artery bypass graft surgery (CABG), a heart valve repair/replacement, or a concomitant CABG and valve surgery were enrolled.

Consented patients were randomized into one of the two groups using a 1:1 randomization sequence generated by a computer program. Randomization sequence and the study drugs were kept in a locked box and were opened only by unblinded study personnel who were not involved in the clinical care of the patient. This person prepared the study drug following the instructions of the study protocol, resulting in preparations of EACA and TA that contained equi-potent similar volumes of the drug in the syringe, in order to ensure blinding. Antifibrinolytic study drug was administered following anesthetic induction. EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in the investigators hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.

The primary endpoint was the amount of chest tube drainage and the amount of blood products used in the first 24 hours following surgery (surrogate measurement for blood loss) was measured at 4, 8, 12 and 24 hours after surgery. The incidence of packed red blood cells (PRBC), fresh frozen plasma (FFP), cryoprecipitate and platelets administered during the first 24 hours after surgery was collected. Additionally, patients were monitored for any complications during their stay in the hospital and up to 30 days post-operatively. Complications included renal dysfunction (defined as the need for at least 1 hemodialysis or doubling of pre-surgical creatinine levels), stroke and seizures (clinically diagnosed), myocardial infarction (new Q waves in two electrocardiogram leads), cardiac arrest, respiratory failure, re-operation and death. Monitoring of the patients prior to discharge involved chart review during their stay in the hospital; if a post-operative complication was suspected, the complication was confirmed using Montefiore Medical Center's Carecast Database, which contained independent results such as MRI's, CT scans, or labs. Additionally, computer records of the patients were searched to determine if there were documented complications in the 30-day post-operative time period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 114 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Supportive Care
Official Title: A Randomized, Double-blinded Trial Comparing the Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery
Study Start Date : October 2008
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Epsilon-aminocaproic acid (EACA)
Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr.
Drug: Epsilon-aminocaproic acid administered
Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.

Experimental: Tranexamic acid (TA)
Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion.
Drug: Tranexamic Acid administered
Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.




Primary Outcome Measures :
  1. Chest tube drainage [ Time Frame: 24 hours ]
    Chest tube drainage are collected from the nursing records, every 6th hourly the amount fluid collected is reported in the collection sheets.

  2. Amount of blood products used [ Time Frame: 24 hours after surgery ]

Secondary Outcome Measures :
  1. Renal dysfunction [ Time Frame: Within 30 days after surgery ]
    Confirmed diagnosis of renal dysfunction and hospitalization for the same within 30 days after the surgery

  2. Myocardial infarction [ Time Frame: Within 30 days after surgery ]
    Confirmed diagnosis of myocardial infraction and hospitalization for the same within 30 days after the surgery

  3. Respiratory arrest [ Time Frame: Within 30 days after surgery ]
    Confirmed diagnosis of respiratory arrest and hospitalization for the same within 30 days after the surgery

  4. Stroke [ Time Frame: Within 30 days after surgery ]
    Confirmed diagnosis of stroke and hospitalization for the same within 30 days after the surgery

  5. Seizure [ Time Frame: Within 30 days after surgery ]
    Confirmed diagnosis of seizure and hospitalization for the same within 30 days after the surgery

  6. Reoperation [ Time Frame: Within 30 days after surgery ]
    Confirmed diagnosis ofreopeartion and hospitalization for the same within 30 days after the surgery

  7. Length of hospital stay [ Time Frame: Within 30 days after surgery ]
  8. Mortality [ Time Frame: Within 30 days after surgery ]

Other Outcome Measures:
  1. Patient Demographics [ Time Frame: Baseline ]
    Measurements taken as a composite. BMI, Sex, Age are to be determined to ensure that the subjects' characteristics were comparable between the Epsilon-aminocaproic Acid and Tranexamic Acid groups.

  2. Type of surgery [ Time Frame: Intraoperative ]
  3. Intraoperative characteristics [ Time Frame: Intraoperative ]
    Measurements are taken as a composite to determine that the subjects' characteristics are comparable between the Epsilon-aminocaproic Acid and Tranexamic Acid groups. Measurements include temperature, Heparin dose, protamine given, time of surgery, time of cardiopulmonary bypass, and aortic clamp time.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Informed consent obtained before any trial-related activities
  • Subjects scheduled to undergo cardiac surgery requiring cardiopulmonary bypass

Exclusion Criteria:

  • Vulnerable patient populations (unable to consent)
  • Religious or other prohibitive reason for not receiving blood transfusion
  • History of allergy to epsilon-aminocaproic acid or tranexamic acid
  • Pregnant or breast-feeding (if applicable)
  • The participation in another clinical or device trial that would affect the patient's coagulation profile
  • Cardiac or cardiopulmonary transplantation procedure
  • Any history of stroke and/or non-coronary thrombotic disorders (DVT, PE)
  • Clinical signs consistent with non-coronary thrombotic disease
  • Known congenital deficiency of Protein C, Protein S, Antithrombin and homozygous Factor V Leiden
  • Known congenital bleeding disorders
  • Weight < 50 kg
  • Weight > 150 kg
  • Acute renal failure or creatinine > 2.0 mg/dL
  • Current surgery including any implantable ventricular assist device requiring CPB including ECMO (extracorpeal membrane oxygenation)
  • Current surgery including the aortic arch and/or descending thoracic aorta
  • Any changes to the planned surgery, which result int he patient not requiring CPB or meeting exclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02655653


Sponsors and Collaborators
Montefiore Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Jonathan D Leff, MD Montefiore Medical Center

Layout table for additonal information
Responsible Party: Montefiore Medical Center
ClinicalTrials.gov Identifier: NCT02655653     History of Changes
Other Study ID Numbers: 08-08-291
First Posted: January 14, 2016    Key Record Dates
Last Update Posted: May 5, 2016
Last Verified: January 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Tranexamic Acid
Aminocaproic Acid
Hemorrhage
Pathologic Processes
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Hemostatics
Coagulants